Armata Pharmaceuticals (ARMP) Income from Continuing Operations (2013 - 2026)
Armata Pharmaceuticals (ARMP) reported Income from Continuing Operations of 67182000.0 for Q1 2026, down 469.68% on a YoY basis from 18173165.57 in Q1 2025, and down 344.47% sequentially from 15115000.0 in Q4 2025.
Armata Pharmaceuticals (ARMP) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals (ARMP) has 14 years of Income from Continuing Operations data on file, last reported at 67182000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 469.68% year-over-year to 67182000.0; the trailing twelve-month figure through Mar 2026 stood at 163535000.0 (up 13.14% YoY), and the FY2025 full-year result was 134410000.0, down 6.12% from the prior year.
- Income from Continuing Operations eased to 67182000.0 in Q1 2026, from 15115000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 10011000.0 in Q3 2022 to a low of 81329000.0 in Q2 2024.
- A 5-year average of 27957908.94 and a median of 14994000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 561.76% in 2024 and surged 84.68% in 2025, its largest moves.
- Tracing ARMP's Income from Continuing Operations over 5 years: stood at 10315452.0 in 2022, then slumped by 143.59% to 25127000.0 in 2023, then grew by 23.29% to 19275000.0 in 2024, then grew by 21.58% to 15115000.0 in 2025, then slumped by 344.47% to 67182000.0 in 2026.
- Business Quant data shows ARMP's Income from Continuing Operations at 67182000.0 in Q1 2026, 15115000.0 in Q4 2025, and 68778000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Armata Pharmaceuticals | 191.29 Mn | 186.49 Mn | - | -67.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.18 Mn |
| Dec 31, 2025 | -15.12 Mn |
| Sep 30, 2025 | -68.78 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -11.79 Mn |
| Dec 31, 2024 | -19.28 Mn |
| Sep 30, 2024 | -75.87 Mn |
| Jun 30, 2024 | -81.33 Mn |
| Mar 31, 2024 | -13.53 Mn |
| Dec 31, 2023 | -25.13 Mn |
| Sep 30, 2023 | -11.47 Mn |
| Jun 30, 2023 | -14.99 Mn |
| Mar 31, 2023 | -16.53 Mn |
| Dec 31, 2022 | -10.32 Mn |
| Sep 30, 2022 | -10.01 Mn |
| Jun 30, 2022 | -10.14 Mn |
| Mar 31, 2022 | -11.37 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | -6.75 Mn |
| Jun 30, 2021 | -7.31 Mn |